Galapagos NV
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
15 okt 2015 - 07:30
Statutaire naam
Galapagos NV
Titel
Galapagos advances triple combination therapy in cystic fibrosis
Bericht
- GLPG2665, a next-generation (C2) corrector, together with the other two components of the triple combination, show up to six-fold greater chloride transport than Orkambi1) in vitro
- Triple combination therapy of C2 with GLPG2222 and GLPG1837 expected to address 80% of mutations in the CF population
- Multiple series of C2 correctors identified, each with unique mode of action
- GLPG2665 enters pre-clinical development and completes the first Galapagos-AbbVie triple combination therapy
Datum laatste update: 05 januari 2026